This site is intended for health professionals only

Published on 19 August 2010

Share this story:
Twitter
LinkedIn

HIV drug available to more patients

teaser

The All Wales Medicines Strategy Group (AWMSG) has extended recommendations for the use of an HIV drug.

Isentress (raltegravir; Merck, Sharpe & Dohme) can now be used by those who cannot take these types of medicines due to drug-drug interactions (PDF, 190k) or in combination with other antiretroviral medicines, for the treatment of HIV-1 infection in any adults who are resistant to or intolerant of non-nucleoside reverse transcriptase inhibitors or protease inhibitors.

However, the recommendations made by the AWMSG in 2008 for the use of the drug in treatment-experienced adults still applies.

The AWMSG has ruled that the prescribing of Revatio should be restricted to a doctor experienced in treating this condition in association with a National Commissioning Group-designated expert centre.

Also recommended for use within its current licensed indication to improve the exercise capacity of patients with pulmonary arterial hypertension (PDF, 150K), is hypertension drug Revatio (sildenafil; Pfizer).

Copyright Press Association 2010

All Wales Medicines Strategy Group



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn